EAM Global Investors’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

EAM Global Investors’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-209,856	Closed	-$2.22M	–	215
2022 Q4	$2.22M	Buy	+209,856	New	+$1.69M	0.57%	54
2020 Q3	–	Sell	-69,564	Closed	-$982K	–	186
2020 Q2	$982K	Sell	69,564 -72,659	-51%	-$917K	0.44%	109
2020 Q1	$1.31M	Buy	+142,223	New	+$1.83M	0.77%	66
2019 Q4	–	Sell	-18,259	Closed	-$125K	–	157
2019 Q3	$125K	Sell	18,259 -57,532	-76%	-$582K	0.06%	113
2019 Q2	$917K	Buy	+75,791	New	+$413K	0.39%	121

Other funds holding PRVB

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

EAM Global Investors's PRVB Position: Q1 2023 in Review

EAM Global Investors sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2023, closing a stake of 209,856 shares — an estimated $2.22M sold.

EAM Global Investors first reported a position in PRVB in Q2 2019 and held it in 5 quarters. The position peaked at $2.22M in Q4 2022. 182 funds tracked by Wall St. Rank hold PRVB as of Q1 2023.

EAM Global Investors reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
EAM Global Investors sold 209,856 Provention Bio, Inc. Common Stock shares in Q1 2023, an estimated $2.22M.
EAM Global Investors first reported a position in Provention Bio, Inc. Common Stock in Q2 2019 and held it in 5 quarters.
EAM Global Investors's Provention Bio, Inc. Common Stock position peaked at $2.22M in Q4 2022.
182 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2023.

Based on EAM Global Investors's 13F filing for Q1 2023, filed 15 May 2023.